Sinopharm Group Co (1099.HK) Stock Price
Sinopharm Group Co Price
Revenue has compounded at 18.3% per year over the past 19 years to 669.46 B CNY. Earnings per share have grown at 17.3% per year over the last 19 years. Sinopharm Group Co's net margin stands at 1.2%, broadly stable from 1.5% several years earlier. Sinopharm Group Co currently offers a dividend yield of about 5.46%. The payout ratio is around 28% of earnings. The dividend has grown at 33.1% per year over the past 15 years. Analysts set a median price target of 20.02 CNY, implying 47.8% above the current price. Of 23 analysts, 16 rate the stock a buy — an overall Buy consensus.
Sinopharm Group Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Sinopharm Group Co business model & stock analysis
Frequently asked questions about Sinopharm Group Co
The business model of Sinopharm Group Co Ltd focuses on providing pharmaceutical and healthcare products and services. Sinopharm Group operates through various segments, including Distribution, Retail Pharmacy, Pharmaceutical Manufacturing, and others. As China's largest pharmaceutical distribution and retail company, Sinopharm Group plays a crucial role in the healthcare industry. The company offers a wide range of products, including prescription drugs, over-the-counter medicines, medical devices, and healthcare services. Sinopharm Group aims to enhance the accessibility and affordability of quality healthcare by ensuring the efficient supply chain and expanding its reach across different regions in China.
Sinopharm Group Co Ltd is primarily active in the healthcare industry.
The main competitors of Sinopharm Group Co Ltd in the market are Shanghai Fosun Pharmaceutical Group Co Ltd, China Resources Pharmaceutical Group Ltd, and CSPC Pharmaceutical Group Ltd.
Sinopharm Group Co Ltd, a renowned pharmaceutical and healthcare company, has a rich history and stellar background. Established in 2003, Sinopharm has emerged as a leading player in the healthcare industry. It operates in various segments, including distribution, retail, manufacturing, research, and more. With headquarters in Beijing, China, Sinopharm has focused on expanding its operations globally, establishing a presence across 150 countries. The company strives to improve healthcare accessibility and quality by offering a wide range of products and services, including pharmaceuticals, medical devices, and healthcare solutions. Sinopharm Group Co Ltd's commitment to innovation, quality, and professionalism has earned it a strong reputation in the global market.
Sinopharm Group Co Ltd has achieved several significant milestones throughout its history. One notable accomplishment is the company's successful listing on the Hong Kong stock exchange in 2009, followed by its inclusion in the Hang Seng Index in 2011. Sinopharm has also made significant advancements in the healthcare industry, expanding its portfolio through acquisitions and strategic collaborations. Notably, the company established Sinopharm Holding Guoda Drugstore, an integrated pharmaceutical retailer. In addition, Sinopharm is at the forefront of medical research and development, collaborating with international pharmaceutical companies and contributing to the innovation of new drugs. Sinopharm Group Co Ltd continues to strive for excellence and cement its position as a leading global healthcare company.
Sinopharm Group Co Ltd is primarily present in China.
Sinopharm Group Co Ltd represents the values of integrity, innovation, and excellence. The company is guided by a corporate philosophy that prioritizes customer-centricity and social responsibility. With a focus on healthcare, Sinopharm Group Co Ltd strives to provide high-quality medical products and services to people worldwide. Through continuous research and development, they aim to improve healthcare access and enhance well-being. By upholding its values and corporate philosophy, Sinopharm Group Co Ltd actively contributes to the advancement of the global healthcare industry, making a positive impact on people's lives.
Analysts currently set an average price target of 19.41 CNY for the Sinopharm Group Co stock (median: 20.02 CNY), implying +43.3 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Sinopharm Group Co stock: 16 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Sinopharm Group Co to generate revenue of 588.45 B CNY and earnings per share of 2.34 CNY.
Converted at the current exchange rate, the Sinopharm Group Co share trades at 1.80 EUR (13.54 CNY).
The Sinopharm Group Co share (1099.HK) is listed on 5 stock exchanges, including: Hongkong (HKEX) (1099.HK), Frankfurt (X2S.F), München (X2S.MU), Düsseldorf (X2S.DU).
Sinopharm Group Co Ltd is a leading Chinese company specializing in the manufacturing and marketing of pharmaceutical products, medical devices, vaccines, health products, and services. The company covers a wide range of business areas, including the production of medicines, vaccines, medical devices, and medical services. It focuses on customizing its offerings to meet the needs of end customers, establishing itself as a strong player in the global market. The company's main emphasis is on the production and marketing of pharmaceutical products, including a wide range of medicines and medical devices such as eye drops, cough and cold medicines, vitamins and minerals, painkillers, antibiotics, and cancer therapeutics. Sinopharm Group Co Ltd is also a leading provider of vaccines, producing and distributing a broad range of vaccines including those for Hepatitis B, rabies, measles, mumps, and rubella. Additionally, the company offers health products like dietary supplements, diagnostic devices, and medical accessories. It also develops and manufactures medical devices such as urinary catheters, implants, and stents. In addition to these areas, Sinopharm Group Co Ltd is also involved in other segments of the healthcare industry such as hospital management and medical services. It operates a chain of hospitals and pharmacies in China, providing medical services such as consultations, diagnoses, prevention, and rehabilitation. The company's business model is focused on offering products and services tailored to the needs and demands of customers. It invests in research and development to create innovative and cost-effective products and solutions.
The expected revenue of Sinopharm Group Co is 588.45 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Sinopharm Group Co is 7.31 B CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Sinopharm Group Co is currently 5.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sinopharm Group Co stock.
The price-to-sales ratio (P/S) of Sinopharm Group Co is currently 0.07. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sinopharm Group Co stock.
The Eulerpool Quality Score for Sinopharm Group Co is 6/10.
The ISIN of Sinopharm Group Co is CNE100000FN7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Sinopharm Group Co is A0N99U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Sinopharm Group Co is 1099.HK. The ticker symbol is used to trade Sinopharm Group Co shares on the stock exchange.
Sinopharm Group Co stock
Sinopharm Group Co Peer Group
Sinopharm Group Co Ticker
Sinopharm Group Co FIGI
All fundamentals and in-depth analysis of Sinopharm Group Co
Our stock analysis for Sinopharm Group Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinopharm Group Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.